Page 102 - Clinical Program In Primary Sclerosing Cholangitis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Clinical program in primary sclerosing cholangitis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Clinical Program In Primary Sclerosing Cholangitis Today - Breaking & Trending Today

DGAP-News: Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis

DGAP-News: Immun .
DGAP-News: Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis
vom 18.02.2021, 12:30 Uhr
Bild: pixabay.com
DGAP-News: Immunic, Inc.
/ Key word(s): Study results
Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis
18.02.2021 / 12:30
The issuer is solely responsible for the content of this announcement.
Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis
- Statistically Significant Decrease in Serum Alkaline Phosphatase (ALP) Levels in the Per-Protocol Population After 24-Week IMU-838 Treatment, as Compared to Baseline - ....

United States , Paula Schwartz , Edna Kaplan , Keith Lindor , Johne Eaton , Daniel Vitt , Elizabeth Carey , Jessica Breu , Andreas Muehler , Department Of Internal Medicine , Division Of Gastroenterology , National Institutes Of Health , Rx Communications Group , Distribution Services , Exchange Commission , Us Food Drug Administration , Immunic Inc , Concept Clinical Trial , Primary Sclerosing Cholangitis , Primary Sclerosing , Significant Decrease , Serum Alkaline Phosphatase , Per Protocol Population After , Therapeutic Benefit Achieved , Per Protocol Population , Liver Biochemistry Parameters Remained Stable ,

BioNTech SE: Pfizer and BioNTech Commence Global Clinical Trial to Evaluate COVID-19 Vaccine in Pregnant Women

Phase 2/3 trial will enroll approximately 4,000 healthy pregnant women in the U.S., Canada, Argentina, Brazil, Chile, Mozambique, South Africa, U.K., and SpainFirst participants dosed in the U.S. Women ....

New York , United States , United Kingdom , South Africa , Sylke Maas , William Gruber , Chuck Triano , Fosun Pharma , Jerica Pitts , Invasive Groupb Streptococcus Infection Phase , Bayer Animal Health , European Union , Centers For Disease , Pfizer Inc Nasdaq , Drug Administration , Vaccine Clinical Research , Exchange Commission , Roche Group , Vaccine Administration Under Emergency Use Authorization , Senior Vice President , Chief Medical Officer , Respiratory Syncytial Virus , Invasive Groupb Streptococcus Infection , Marketing Authorizations Holder , Emergency Use Authorization , Disease Control ,

MAINTAINING READINESS IN THE AGE OF CORONAVIRUS

Download
By clicking Download you agree to to sign up for the C4ISRNET Market Intelligence Newsletter to receive similar content.
By clicking ‘Download’ you also agree to share your information with Ortho Clinical. Ortho Clinical s use of that information is subject to its own separate privacy policy, which may differ from ours.
Fill out this form to initiate your download.
©2021 Sightline Media Group. All rights reserved.
Learn more about:
The gaps in the DoD s current COVID-19 strategy and how it should change
What the DoD would need in order to put troops at less risk for contracting COVID-19 ....

Intelligence Newsletter , Ortho Clinical , Defense News , White Paper , Corona Virus , Co Vid , Covid 19 , உளவுத்துறை செய்திமடல் , எலும்பியல் மருத்துவ , பாதுகாப்பு செய்தி , வெள்ளை காகிதம் , கொரோனா வைரஸ் , இணை வித் ,

AIM ImmunoTech Inc.: AIM ImmunoTech Announces Ethics Committee Approval to Commence Phase 1 Clinical Study of Ampligen as an Intranasal Therapy

(2)
OCALA, Fla., Feb. 16, 2021 (GLOBE NEWSWIRE) AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has received approval from the required Ethics Committee in the Netherlands to commence its Phase 1 clinical study on the safety of AIM s drug Ampligen as an intranasal therapy, a critical step in the company s ongoing efforts to develop Ampligen as a potential prophylaxis or treatment for COVID-19 and other respiratory viral diseases.
Earlier this year, the company announcedthat it had entered into a sponsorship agreement with the Centre for Human Drug Research (CHDR) for the proposed AMP-COV-100 (CHDR2049) trial. Last week, approval was received from the Dutch local Ethics Committee, clearing the road for execution of the trial. ....

United States , Matthijs Moerland , Thomask Equels , Centre For Human Drug Research , Immunotech Inc , Crescendo Communications , Ethics Committee , Human Drug Research , Antiviral Research , Utah State University , Private Securities Litigation Reform Act , ஒன்றுபட்டது மாநிலங்களில் , மையம் க்கு மனிதன் மருந்து ஆராய்ச்சி , பிறை தகவல்தொடர்புகள் , நெறிமுறைகள் குழு , மனிதன் மருந்து ஆராய்ச்சி , உட்டா நிலை பல்கலைக்கழகம் , ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் ,

DGAP-News: Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial

DGAP-News: Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial
Table: IMU-838 Shows Acceleration of Time to Clinical Improvement
High-risk patients and patients aged over 65 years experienced a more substantial treatment benefit from IMU-838 than in the general patient population:
- The 75% probability
[5] to reach clinical improvement (based on investigator assessment) was accelerated by 3.8 days in IMU-838 treated high-risk patients
[6], as compared to placebo (FAS).
- The 75% probability
[5] to reach clinical improvement (based on investigator assessment) was accelerated by 4.8 days in IMU-838 treated elderly patients (65 years or older), as compared to placebo (FAS). ....

United States , Paula Schwartz , Edna Kaplan , Jessica Breu , Andreas Muehler , Daniel Vitt , Exchange Commission , World Health Organization , Rx Communications Group , Immunic Inc , Distribution Services , Announces That Oral Treatment , Clinical Activity , Multiple Secondary Endpoints , Including Clinically Meaningful Improvements , Clinical Recovery , Clinical Improvement , Very Low Rates , Serious Complications , Hospitalized Patients With Moderate , Risk Patients , Patients Aged Over , More Substantial Treatment Effect , Anti Inflammatory Effect Observed , More Effective Reduction , C Reactive Protein ,